Clinical trial · no report yet · Phase 3
PSMA-DC
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- NCT05939414 ↗
- Recruiting
- Novartis Pharmaceuticals
- 30 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| Podcasts | 9 | |
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Oligometastatic Prostate Cancer (OMPC)
- Interventions
- AAA617; piflufolastat (18F); gallium (68Ga) gozetotide (25μg)
- Arms
- Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617) · Experimental
- Control arm: observation (watchful waiting) · No intervention
- Enrollment
- 450 (estimated)
- Primary outcomes
- Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)
- Sponsor
- Novartis Pharmaceuticals
- Start
- Mar 12, 2024
- Primary completion
- Apr 25, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05939414 · updated Sep 22, 2026